Skip to main content

Table 1 Baseline characteristics and outcome

From: Extracorporeal membrane oxygenation in Pneumocystis jirovecii pneumonia: outcome in HIV and non-HIV patients

 All (n = 18)HIV (n = 6)non-HIV (n = 12)p value
Age (years)49.7 ± 18.436.8 ± 9.756.2 ± 18.60.032
Sex (male)11 (61.1%)4 (66.7%)7 (58.3%)1.0
BMI (kg/m2)24.6 ± 3.423.0 ± 4.225.5 0 ± 2.60.149
Underlying pulmonary disease*2 (11.1%)0 (0%)2 (16.7%)0.407
Comorbidities
 Hypertension5 (27.8%)0 (0%)5 (41.27%)0.114
 Renal insufficiency2 (11.1%)0 (0%)2 (16.7%)0.529
 Chronic haemodialysis1 (5.6%)0 (0%)1 (8.3%)1.0
MV pre-ECMO
 PEEP (mbar)14.9 ± 3.113.8 ± 2.915.3 ± 3.20.489
 Plateau pressure (mbar)28.5 ± 4.629.3 ± 4.028.2 ± 4.90.571
 Driving pressure (mbar)13.6 ± 4.215.5 ± 4.512.9 ± 4.10.412
 Tidal volume (ml)390.7 ± 107.9362.5 ± 104.4400.9 ± 112.30.571
 Minute volume (l/min)9.9 ± 3.610.6 ± 4.39.6 ± 3.50.571
 Compliance (ml/mbar)32.7 ± 15.823.3 ± 10.435.5 ± 17.00.226
 FiO2 (%)83.8 ± 19.487.5 ± 19.481.8 ± 19.40.660
 Horowitz index (mmHg)87.6 ± 37.690.8 ± 40.885.8 ± 37.61.0
 D(A-a)O2 (mmHg)466.4 ± 133.4481.7 ± 132.9458.1 ± 139.40.884
MV duration before ECMO (days)5.4 ± 5.49.3 ± 6.53.3 ± 3.30.048
Acute renal failure3 (16.7%)0 (0%)3 (25.0%)0.276
LDHmax (U/l) before ECMO734.1 ± 268.2577.2 ± 182.1812.5 ± 275.50.083
Scores
 SOFA score9.7 ± 3.68.7 ± 3.410.3 ± 3.70.733
 APACHE II score24.9 ± 8.125.0 ± 9.024.9 ± 8.10.961
 RESP score− 3.3 ± 3.2− 2.8 ± 1.9− 3.55 ± 3.81.0
Successful ECMO weaning7 (38.9%)3 (50%)4 (33.3%)0.494
Survival4 (22.2%)3 (50%)1 (8.3%)0.045
ICU length of stay (days)26.2 ± 20.533.8 ± 15.422.4 ± 22.30.053
ECMO duration (days)13.2 ± 8.713.8 ± 11.012.9 ± 7.80.892
MV duration (days)20.8 ± 14.825.2 ± 17.118.4 ± 13.70.462
Acute haemodialysis6 (33.3%)0 (0%)6 (50.0%)0.054
Prone position while ECMO11 (61.1%)5 (83.3%)6 (50.0%)0.588
  1. ICU intensive care unit, MV mechanical ventilation
  2. *Underlying pulmonary disease: lung fibrosis (n = 2)
  3. ICU and hospital survival